In order to make CRC cells more susceptible to chemotherapy and maybe even overcome chemoresistance, it is suggested that MALAT-1 and its interaction with EZH2 may represent attractive therapeutic targets [72]. The gene discussed is MALAT1; the disease is colorectal carcinoma.